Drug intelligence / Profile preview

AD010

Development stage: Preclinical
Lead developer: AIDEA PHARMA
Modality: Small Molecules

Overview

AD010 is a small molecule drug candidate under development by Jiangsu Aidea Pharmaceutical Group. It is specifically being investigated for the treatment of disseminated intravascular coagulation (DIC), a complex thrombohemorrhagic disorder characterized by systemic activation of blood coagulation. Currently in the preclinical stage, the drug aims to address the pathological activation of the coagulation cascade that leads to microvascular thrombosis and subsequent consumption of clotting factors. Detailed information regarding its specific molecular target or pharmacological mechanism of action has not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on AD010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD010.

Explore the full profile